Molecular Genetics of Hereditary Endoplasmic Reticulum Diabetes
遗传性内质网糖尿病的分子遗传学
基本信息
- 批准号:10417734
- 负责人:
- 金额:$ 56.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAnti-Inflammatory AgentsBeta CellBioinformaticsBiological AssayCalciumCardiovascular DiseasesCell DeathCell LineCell SurvivalCell modelCell physiologyCellsCessation of lifeChemicalsClinical DataComplexDatabasesDiabetes MellitusDiseaseEndoplasmic ReticulumEpilepsyEtiologyFailureFunctional disorderGenesGeneticGenetic studyGlucoseHomeostasisINS geneInheritedInsulinInsulin-Dependent Diabetes MellitusMetabolic DiseasesMicrocephalyModelingModificationMolecularMolecular ChaperonesMolecular GeneticsMutateMutationNon-Insulin-Dependent Diabetes MellitusOrganellesOxidation-ReductionPathogenicityPathway interactionsPharmaceutical PreparationsPhenotypeProteinsRegulationRoleSyndromeTestingTherapeuticVariantWFS1 geneWolcott-Rallison syndromeWolfram Syndromedata ecosystemdesigndisease phenotypeefficacy testingendoplasmic reticulum stressgenetic variantgenetically modified cellsgenomic datainduced pluripotent stem cellinsulin secretionlipid metabolismmutantnoveloverexpressionprecision medicineprotein foldingresponsesmall moleculetherapy design
项目摘要
Abstract
The endoplasmic reticulum (ER) is best known for its role as the locus of protein folding, calcium storage, and
lipid metabolism. The organelle also integrates numerous other molecular pathways and contributes to cellular
calcium homeostasis, reduction-oxidation regulation, and cell death. Given the many vital and complex functions
of the ER, it is little wonder that its failure can trigger a range of diseases. It has been shown that dysregulation
of ER homeostasis may underlie β cell dysfunction and death in type 1 and type 2 diabetes, as well as in
monogenic forms of diabetes, including Wolfram syndrome, Wolcott-Rallison syndrome, microcephaly, epilepsy,
and diabetes syndrome (MEDS), and mutant insulin gene-induced diabetes caused by pathogenic variants in
the WFS1 and CISD2, EIF2AK3, IER3IP1, and INS genes respectively. To further understand the contribution
of ER dysfunction to β cell death and design novel treatments targeting ER for diabetes, we need to establish
functional studies of gene variants affecting ER homeostasis, design treatments targeting common molecular
pathways altered in ER stressed β cells, and identify other ER genes involved in β cell dysfunction and death. In
this proposal, we will characterize WFS1 and CISD2, EIF2AK3, IER3IP1, and INS variants using functional
assays and bioinformatics and test novel treatments targeting the common molecular pathways altered in β cells
expressing pathogenic variants of WFS1 and CISD2, EIF2AK3, IER3IP1, and INS genes. Successful completion
of this study will lead to the establishment of precision medicine for hereditary ER diabetes.
抽象的
内质网 (ER) 以其作为蛋白质折叠、钙储存和代谢场所的作用而闻名。
脂质代谢。该细胞器还整合了许多其他分子途径,并有助于细胞
钙稳态、氧化还原调节和细胞死亡。鉴于许多重要且复杂的功能
急诊室的故障会引发一系列疾病,这也就不足为奇了。研究表明,失调
ER 稳态的改变可能是 1 型和 2 型糖尿病以及 β 细胞功能障碍和死亡的基础
单基因糖尿病,包括 Wolfram 综合征、Wolcott-Rallison 综合征、小头畸形、癫痫、
和糖尿病综合征(MEDS),以及由胰岛素基因突变引起的致病性变异引起的糖尿病
分别是WFS1和CISD2、EIF2AK3、IER3IP1和INS基因。进一步了解贡献
ER 功能障碍对 β 细胞死亡的影响并设计针对 ER 的糖尿病新疗法,我们需要建立
影响内质网稳态的基因变异的功能研究,设计针对常见分子的治疗方法
ER 应激 β 细胞中通路的改变,并鉴定出与 β 细胞功能障碍和死亡有关的其他 ER 基因。在
在本提案中,我们将使用函数来表征 WFS1 和 CISD2、EIF2AK3、IER3IP1 和 INS 变体
分析和生物信息学,并测试针对 β 细胞中改变的常见分子途径的新疗法
表达 WFS1 和 CISD2、EIF2AK3、IER3IP1 和 INS 基因的致病变异。顺利完成
这项研究将导致遗传性 ER 糖尿病精准医学的建立。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bohdan Khomtchouk其他文献
Bohdan Khomtchouk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bohdan Khomtchouk', 18)}}的其他基金
Molecular Genetics of Hereditary Endoplasmic Reticulum Diabetes
遗传性内质网糖尿病的分子遗传学
- 批准号:
10615191 - 财政年份:2022
- 资助金额:
$ 56.95万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 56.95万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 56.95万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 56.95万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 56.95万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 56.95万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 56.95万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 56.95万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 56.95万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 56.95万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 56.95万 - 项目类别:














{{item.name}}会员




